Resolutely focused on science
01
Our Mission
We’re Exert Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare diseases. Led by industry experts, we're developing innovative oral small molecule therapies to revolutionize the treatment of rare genetic disorders.
Pioneering science to transform lives in MPS
02
Our Motivation
We’re evolving treatments for Mucopolysaccharidoses (MPS), a group of lysosomal storage disorders with critical unmet needs.
With long experience working in lysosomal storage disorders, and MPS in particular, our team have met many families affected by MPS and worked with expert physicians dedicated to help them.
Witnessing the determination of those affected by MPS drives us to want to make a difference.
Find out more about MPS:
Inspired by their courage
Mucopolysaccharidoses (MPS) explained
Mucopolysaccharidoses (type I to VII) are caused by the lack of an enzyme due to a genetic defect.
These enzymes are needed to break down glycosaminoglycans (GAGs), which build up in the cells and damage them.
Devastating diseases leading to a reduced life expectancy and very poor quality of life.
Find out more about MPS:
03
Our Science
We’re looking to change the way that MPS is treated by delivering treatments that aim to go beyond current therapies, leading to a more complete therapeutic response.
Determined to make a difference in MPS
PROGRAM 1
The lead program has demonstrated promising Phase IIa clinical proof-of-concept data in mucopolysaccharidosis type VI (MPS VI) and holds the potential to address other MPS subtypes.
PROGRAM 2
Our second program is a novel discovery-stage therapy for MPS III with a unique mechanism of action.
05
Contact Us
Ready to Partner with Us?
Contact us today.
David Boothe
Co-founder and CEO
David has over 30 years of industry experience with 20+ spent in rare diseases, during which he led the commercial launches of several drugs, including the current treatment for MPS VI.
GSK | BioMarin | Spark | Shire | Orion
William Hariri
Co-founder and CBO
William has 12 years of Corporate Development experience with senior management positions in investment banks and in a clinical stage biotech as CBO. He has led numerous successful transactions.
Alira Health | Locust Walk | Enterome
Dr Aidan Gill
Medical Advisor
UK-registered Physician with 20+ years in Rare Diseases, spanning all phases of drug development globally. Expertise from clinical trial to strategic leadership.
Shire | PTC | Roche | Takeda
John Watson
Regulatory Advisor
John has 40+ years of experience in regulatory affairs, having led the approval of numerous rare disease and paediatric drugs.
Pharmion | NPS | ViroPharma | Zogenix | Biogen
Dr Tony Clarke
Drug Development Advisor
Tony has extensive leadership experience in R&D and has led multiple companies through acquisitions and global development efforts.
Brabant | Huxley | Amarin | Alexa | Zogenix
Dr Philippe Monteyne
Strategic Advisor
Partner at Aliath Bioventures, is a seasoned life sciences investor and former GSK and Sanofi executive. A neurologist with a PhD, he led the development of key treatments like Cervarix and Strimvelis. He serves on biotech boards across Europe and teaches in Brussels.
We're looking to change the way that rare diseases are treated
05
Investment opportunity
01
Late-stage opportunity
Late-stage opportunity with near term value inflection points (phase IIb and III readout, regulatory filing, approval within 3 to 4 years)
02
Multidisciplinary team
Multidisciplinary team with expertise in rare disease and the ability to execute the development strategy and business plan
03
Clear value
We have a clear value proposition, clinical development plan and targets a defined patient population with high unmet medical needs
04
Business plan
Strong business case in MPS VI (~$500M market) and other MPS subtypes ($1B+)
05
Flexible strategy
Flexible exit scenarios, plan to establish a fully integrated commercial rare disease player, with potential for earlier exit at near term inflection points
04
Our Team
Multidisciplinary team with expertise in rare disease and the ability to execute the development strategy and business plan